Menu Close

Alzheimer’s and aducanumab: Unjust profits and false hopes

The U.S. Food and Drug Administration’s controversial decision to approve aducanumab for the treatment of Alzheimer’s disease raises at least three major ethical issues that need to be addressed, states a new article in the Hastings Center Report: